论文部分内容阅读
平行设计研究164例纽约心脏协会确诊的心功能Ⅱ或Ⅲ级的心衰患者随机接受enoximone 50mg 每日3次或100mg 每日3次,或者接受安慰剂作对照。全部患者均接受地高辛和/或利尿剂,且左心室射血分数≤45。在治疗1、4、8和12周进行运动试验。结果 enoximone 治疗组比安慰剂组运动时间在4周(P=0.012)、8周(P=0.029)延长,而在12周无变化。enoximone 一次剂量后左心室射血分数明显增加,但长期治疗12周后无变化。心衰症状和心脏的生理分析表
In a parallel design study of 164 New York Heart Association diagnosed patients with heart failure class II or III who received enoximone 50 mg three times daily or 100 mg three times daily or placebo as control. All patients received digoxin and / or diuretic, and left ventricular ejection fraction <45. Exercise tests were performed at 1, 4, 8 and 12 weeks of treatment. Results The exercise duration in enoximone-treated group was longer than that in placebo group at 4 weeks (P = 0.012) and 8 weeks (P = 0.029), but not at 12 weeks. After a dose of enoximone significantly increased left ventricular ejection fraction, but no change after long-term treatment of 12 weeks. Heart failure symptoms and heart physiological analysis table